Scholars@Duke publication: Supplementary Figure S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Supplementary Figure S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Other

Ma, J; Hegde, S; Sergeeva, M; Chakraborty, B; Wardell, SE; McDonnell, DP; Huang, PQ; Bunker, KD; Doñate, F; Lackner, MR; Samatar, AA

April 2, 2026

Published version (DOI) Publisher Link

<p>Supplementary Figure S4 shows Combination of ZN-c5 and palbociclib further arrests the cells at G1 phase A. Relative ER level to DMSO after normalized to β-actin control for Figure 4B. B. MCF-7 cells were treated with 500nM of palbociclib for indicated time, cyclin D1 and p-Rb expression were examined by western blot. C. MCF-7 cells were treated with 100nM ZN-c5 or fulvestrant, 500nM palbociclib, or combination of palbociclib with ZN-c5 or fulvestrant, for 24 hours. Western blot analysis of cyclin D1, pRb, ERα and PR were performed. D. cell cycle analysis of MCF-7 cells treated with ZN-c5 or palbociclib for 48 hours.</p>

Duke Scholars

Author Donald Patrick McDonnell Pharmacology & Cancer Biology

Author Suzanne E Wardell Pharmacology & Cancer Biology

Author Binita Chakraborty

Altmetric Attention Stats

Dimensions Citation Stats

DOI

10.1158/1535-7163.31923577

Publication Date

April 2, 2026

Citation

APA

Chicago

ICMJE

MLA

NLM

Ma, J., Hegde, S., Sergeeva, M., Chakraborty, B., Wardell, S. E., McDonnell, D. P., … Samatar, A. A. (2026). Supplementary Figure S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. https://doi.org/10.1158/1535-7163.31923577

Ma, Jianhui, Sayee Hegde, Masha Sergeeva, Binita Chakraborty, Suzanne E. Wardell, Donald P. McDonnell, Peter Q. Huang, et al. “Supplementary Figure S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models,” April 2, 2026. https://doi.org/10.1158/1535-7163.31923577.

Ma J, Hegde S, Sergeeva M, Chakraborty B, Wardell SE, McDonnell DP, et al. Supplementary Figure S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. 2026.

Ma, Jianhui, et al. Supplementary Figure S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. 2 Apr. 2026. Crossref, doi:10.1158/1535-7163.31923577.

Ma J, Hegde S, Sergeeva M, Chakraborty B, Wardell SE, McDonnell DP, Huang PQ, Bunker KD, Doñate F, Lackner MR, Samatar AA. Supplementary Figure S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. 2026.

DOI

10.1158/1535-7163.31923577

Publication Date

April 2, 2026